Poorly differentiated tumors in non-small cell lung cancer (NSCLC) 
Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths, due to high incidence and lack of effective therapies (1) . NSCLC has heterogeneous pathologies and molecular profiles, which presents challenges to molecular targeting and treatment (2) (3) (4) . The degree of tumor cell differentiation is an independent prognostic factor for clinical outcome: less differentiated tumors are associated with increased risk of death in both squamous cell carcinoma and adenocarcinoma (5) . Strikingly, less differentiated tumors are also associated with increased risk of recurrence after resection (5) . The molecular and cellular bases for these associations are not understood.
Investigation of the cellular heterogeneity in tumors has encouraged new frameworks, such as the cancer stem cell hypothesis, for understanding the cellular hierarchy as it relates to disease progression and for designing therapeutic strategies (6) (7) (8) . These experiments have demonstrated that capacities for self-renewal and differentiation vary among cells in a given tumor. The types and relative proportions of various cell subpopulations in solid tumors are likely major determinants of disease progression and therapeutic responsiveness in cancer patients. In many cases, only certain subpopulations of cancer cells from a tumor can initiate tumor growth in immunodeficient mice. Herein these cells are referred to as tumor-initiating cells (TICs); they are also known in the literature as cancer stem cells and cancer-initiating cells (6) (7) (8) .
TICs have been isolated, enriched or identified in tumors of brain, breast, colon, head and neck, lung, melanoma, pancreas, prostate, and the hematopoietic system, typically with antibodies against cell surface markers (9). In general the tumors grown from TICs p. 4 recapitulate the cellular heterogeneity of the original tumor, which underscores the developmental plasticity of many TICs and the differentiation hierarchy in many tumor tissues.
Tumor cell subpopulations and their distinct roles in disease progression can be studied using a variety of complementary approaches (8) . The isolation of defined cell subpopulations from tumors, xenografts and established cell lines based on cell surface markers allows for an in depth molecular analysis of rather homogenous subpopulations.
The culturing of cancer cells in defined serum-free media and/or three-dimensional matrices has been shown to maintain karyotype, transcriptome and signaling that are reflective of the tissue of origin (10, 11) . Patient-derived xenografts (PDX) are established directly from freshly resected tumors and exhibit rich architectures that reflects the original patient tumors. PDXs are complex yet tractable preclinical models that can be used to study cellular heterogeneity and evaluate the efficacy of therapeutic agents.
Here we apply these emerging frameworks and technologies to delineate a cellular hierarchy in NSCLC and apply the new knowledge to drug discovery. By integrating novel experimental models of NSCLC with the clinicopathological analysis of patient tumors, we identify the 5T4 oncofetal antigen as a marker of undifferentiated, highly tumorigenic cells and of worse clinical outcome. We demonstrate preclinical efficacy of an anti-5T4 antibody-drug conjugate (ADC) and suggest that this therapeutic strategy could be applied to other surface markers expressed on tumor-initiating cells. p. 5
Materials and Methods
Isolation and serum-free culture of human lung tumor cells. Human lung tumor tissue (sample 87426A1) was obtained from Asterand in accordance with appropriate consent procedures, washed in PBS and minced. Fragments were disaggregated with Collagenase III (250 U/ml) at 37°C for 2-3 hrs. Partially digested tissue fragments were passed through steel mesh screens. Cells were sieved through a 40 μm cell strainer (BD Falcon) and treated with red blood cell lysis buffer (Roche). Dead cells were excluded by magnetic separation (Miltenyi Biotec). The culture was established and maintained in serum-free BEBM complete medium (Lonza), which was changed 50% every other day. 
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Results
A cell line model reveals 5T4 expression in tumor-initiating cells
To identify a model of tumor heterogeneity in NSCLC, we screened several cell lines for heterogeneous expression of cell surface markers that had previously been used to enrich or isolate TICs (6, 9) . Staining of the H460T cell line with anti-CD24 and anti-CD44 antibodies revealed distinct subpopulations of cells with a stable distribution over many passages in culture ( Figure 1A and data not shown Figure 1B ). Tumors from CD24 -/lo CD44 hi cells were also larger than tumors from CD24 -/lo CD44 lo cells (p < 0.02; Figure S1A ). In vitro, CD24 -/lo CD44 hi cells migrated more efficiently than CD24 hi CD44 hi cells and exhibited multipotency in that they gave rise to less tumorigenic CD24 hi CD44 hi cells ( Figure S1 and data not shown). Figure S2A ). In addition, analysis of published mRNA data (12) revealed that CD24 -/lo CD44 hi was associated with worse overall survival in adenocarcinomas (p = 0.0501; Figure S2B ). Taken together, these results demonstrated that the TIC markers identified in H460T and HCC2429 were also poor prognosis markers in NSCLC, which indicates the clinical relevance of the cell line models.
From a therapeutic perspective, it is not feasible to target the CD24 -/lo CD44 hi combination of markers. Therefore we sought to identify novel TIC markers in NSCLC that could be potential therapeutic targets. We generated gene expression profiles from triplicate samples of sorted CD24 -/lo CD44 hi and CD24 hi CD44 hi cells from H460T ( Figure   S1E ). The 5T4 (TPBG) gene had significantly higher expression in the more tumorigenic CD24 -/lo CD44 hi cells compared to the CD24 hi CD44 hi cells ( Figure 1C and Table S1 ).
Consistent with this result, in NSCLC clinical samples, 5T4 mRNA expression was significantly higher in CD24 -/lo CD44 hi versus "Not CD24 -/lo CD44 hi " tumors (12) (p = 0.0293; Figure S2C ).
5T4 is a single-pass transmembrane protein that is preferentially expressed in many tumor types compared to normal tissues (13) and has been explored as a cancer target. During embryonic development, 5T4 functions in EMT and cell migration, at least in part by interacting with CXCR4 and/or the actin cytoskeleton (14) (15) (16) (17) . Given the oncofetal characteristics of 5T4 and its increased expression in the tumorigenic CD24 -/lo CD44 hi subpopulation of H460T, we focused on 5T4 as a potential TIC marker in NSCLC.
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Immunofluorescence studies in H460T revealed that staining for 5T4 and CD24
were mutually exclusive, consistent with the gene expression data, and moreover that most if not all CD24 -/lo cells expressed 5T4 ( Figure 1D ). This result was extended by flow cytometry ( Figure S3 ) and immunoblot analysis ( Figure 1E ).
Based on the expression of 5T4 in normal progenitor cells during embryonic development (18), we hypothesized that 5T4 expression is associated with a less differentiated state and that inducing differentiation of tumor cells would reduce 5T4
expression. Sorted cells were treated with retinoic acid and subjected to immunoblot analysis. Indeed, 5T4 expression was dramatically reduced in treated CD24 -/lo CD44 hi cells ( Figure 1E ).
To test tumorigenicity based on 5T4 expression, we sorted cells from a clonal line of H460T and implanted them into mice. As predicted, 5T4 hi cells were more tumorigenic than 5T4 -/lo cells (p < 0.03; Figure 1F ), which indicated that 5T4 can independently enrich for TICs in this system. Based on all of these results, we sought to further establish 5T4 as a novel TIC antigen by using PDXs.
5T4 enriches for tumorigenicity in a patient-derived xenograft
We established NSCLC PDX lines by implanting fragments of freshly resected tumors (squamous cell carcinoma) subcutaneously in immunocompromised mice. Each line was propagated by explanting xenograft fragments into naive animals and was maintained exclusively in vivo. In each PDX line, the histology of the xenograft resembled that of the original tumor (data not shown). To uncover molecular differences between 5T4 hi and 5T4 -/lo cells, we generated gene expression profiles from cells sorted on three independent occasions from 60257A1.
Strikingly, the Clara cell secretory protein (CCSP, also known as uteroglobin, SCGB1A) was expressed 20-fold higher in 5T4 hi cells compared to 5T4 -/lo cells ( Figure 2C ). CCSP has been characterized as a marker of lung stem cells in normal tissue and adenocarcinoma (20) . In addition, several genes associated with tumorigenesis, invasion and stem cells were expressed at higher levels in 5T4 hi cells, including carcinoembryonal antigens CEACAM6 and CEACAM1, cathepsin S, gelsolin, and IL8 ( Figure 2C ). In contrast, low levels of CD133 were comparable in both populations ( Figure S4A ). In p. 11 summary, the gene expression profiles distinguished the 5T4 hi and 5T4 -/lo populations and offered potential explanations for their different tumor-initiating capacities.
5T4 and markers of EMT are expressed in cells near the top of the tumor hierarchy
Immunohistochemical analysis of our PDXs revealed a range of 5T4 expression levels and patterns. Three of six PDX lines exhibited heterogeneous expression of 5T4, and in two of the three, 5T4 expression was coupled to tumor architecture in that expression was higher at the tumor-stroma interface ( Figure 3A , 3B, and Figure S4B ).
Notably, in 37622A1 a pattern similar to 5T4 was observed for vimentin, a marker of EMT, and Ki67, a proliferation marker ( Figure 3A ). Coimmunostaining confirmed that 5T4 hi cells were typically positive for Ki67 in this PDX line ( Figure 3B ).
When a serum-free culture was established from the 37622A1 PDX ( Figure 3C ), the cells exhibited uniformly high 5T4 expression, whereas the PDX exhibited a broader expression range ( Figure 3D ). Since the culture media only supports growth of undifferentiated cells, this result was consistent with the hypothesis that 5T4 is highly expressed on TICs. Strikingly, when the cultured cells were implanted into animals, the resulting tumors exhibited heterogeneous 5T4 expression ( Figures 3E and S4C ). This result suggested that 5T4 hi cells gave rise to 5T4 -/lo cells during tumor growth by a mechanism that potentially requires tumor-stroma interaction or other microenvironmental cues.
To further investigate the cellular hierarchy in NSCLC, we developed a novel three-dimensional (3D) model of lung cancer differentiation. In a serum-free culture 
established directly from freshly resected tumor (sample 87426A1), cells could either be maintained in the undifferentiated state submerged in stem cell media or be induced to differentiate at the air-liquid interface with retinoic acid, but notably without the use of serum ( Figure 4A ). The air-liquid interface is considered a physiological environment for lung cells and used to study differentiation of immortalized bronchial epithelial cells (21) .
The 87426A1 culture efficiently formed a 3D multi-layered epithelium upon exposure to the air-liquid interface for 18 days ( Figure 4B ).
Immunoblot analysis demonstrated that 5T4 levels were high in the undifferentiated state and decreased quickly and dramatically upon differentiation ( Figure   4C ). This result was analogous to retinoic acid treatment of sorted H460T cells ( Figure   1E ).
To obtain a global view of the cellular hierarchy in NSCLC, gene expression profiles were generated from undifferentiated and differentiated cells. Consistent with the above results, 5T4 expression decreased and CD24 expression increased during differentiation ( Figure 4D, 4E) . These data were confirmed by flow cytometry ( Figure   S5 ). The profiles revealed striking patterns of genes involved in EMT and angiogenesis.
The EMT markers vimentin, fibronectin, Slug, and Twist were expressed at significantly higher levels in undifferentiated cells ( Figure 4D ); in contrast, the epithelial differentiation markers mucin and involucrin as well as transglutaminase and cytokeratins were expressed at significantly higher levels in differentiated cells ( Figure 4E ). The coexpression of 5T4 and vimentin in undifferentiated cells was consistent with the similar expression patterns of 5T4 and vimentin in 37622A1 PDX ( Figure 3A) . Interestingly, angiogenesis factors including VEGF-A, VEGF-C, PDGF-A, and PIGF and uPA, were p. 13 expressed at significantly higher levels in undifferentiated cells ( Figure 4F ). These results are noteworthy given the higher 5T4 expression at the tumor-stroma interface in two of our PDX lines.
An unbiased meta-analysis revealed several gene signatures with significant expression changes during differentiation (Supplemental Table S2 
Correlation between 5T4 expression and clinicopathologic features and disease outcomes
We sought to determine whether 5T4 expression in NSCLC tumors correlated with clinicopathologic features and disease outcomes. In a panel of surgically resected tumors, 5T4 expression levels and patterns varied, and each sample was assigned an overall score. The distribution of 5T4 expression according to clinicopathological characteristics is shown in Table S3 . Notably, membranous 5T4 expression was higher in poorly and moderately versus well differentiated tumors (p = 0.0005 and p = 0.0197 respectively, with overall ANOVA yielding p = 0.0022; see Table S5 ). In addition, high membranous 5T4 expression was associated with shorter survival time (p = 0.0283, Figure 5A p. 14 0.078 in multivariate analysis, Table S5 ) and shorter time to recurrence (p = 0.0495, Figure 5B ; and p = 0.034 in multivariate analysis, Table S4 ). When the cohort was stratified by 5T4 hi and 5T4 -/lo , there was no difference in the impact of patient treatment on clinical outcome (not shown). These observations are consistent with our experimental results that indicate that 5T4 is associated with less differentiated, more tumorigenic cells in NSCLC.
An antibody-drug conjugate is specifically cytotoxic to 5T4-expressing cells
Taken together, these results provided the rationale for targeting 5T4-expressing cells with an antibody-drug conjugate (ADC) even in tumors with heterogeneous 5T4
expression. Unconjugated anti-5T4 monoclonal antibody has not exhibited any in vitro activity or in vivo efficacy (22) . To generate the ADC, anti-5T4 antibody (13), previously shown to internalize into cells (22) , was conjugated to the enediyne natural product calicheamicin, a DNA damaging agent (23) ( Figure 6A ). To demonstrate specificity for 5T4-expressing cells, in vitro experiments were performed on sorted H460T cells. In a proliferation assay, the 5T4-enriched population was >10-fold more sensitive to the ADC than the 5T4-low population ( Figure 6B ). In a colony formation assay in which cells were treated with drug and then seeded at low density, the 5T4-enriched population was similarly >10-fold more sensitive to the ADC than the 5T4-low population ( Figure 6C ).
In contrast, no difference in sensitivities was observed when the two populations were treated with calicheamicin alone, anti-CD22 calicheamicin ADC, camptothecin, 5- 
Regression of tumors with heterogeneous 5T4 expression with an ADC
We hypothesized that a therapeutic agent that targets and eliminates 5T4
hi -expressing
TICs could ultimately cause regression of tumors despite heterogeneous expression of 5T4 within the tumor. The stable chemical linker between antibody and drug restricts the release of calicheamicin to cells that internalize the ADC (24) . We assessed the efficacy of an anti-5T4 ADC on the growth of two PDX lines with heterogeneous 5T4 expression.
In both lines 5T4 expression was predominant at the tumor-stroma interface, but the overall 5T4 expression level was higher in 37622A1 than 60274A1 ( Figure S4B, S4D ).
37622A1 tumors harbored a K-ras G13V mutation while 60274A1 tumors had wildtype K-ras ( Figure 6D , 6E).
PDX tumors were treated with anti-5T4 ADC, anti-CD33 ADC or vehicle; the anti-CD33 ADC served as a negative control because these PDX lines do not express CD33 (data not shown). In 37622A1, treatment with anti-5T4 ADC regressed the tumors, and no regrowth was observed even three months after the last dose; in contrast, treatment with anti-CD33 ADC or vehicle did not inhibit tumor growth ( Figure 6D ).
Similarly, in 60274A1 treatment with anti-5T4 ADC regressed the tumors despite the lower 5T4 expression in this line ( Figure 6E ). Treatment with calicheamicin (not conjugated to an antibody) has not shown any significant impact on tumor growth (22, 24, 25) . 
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In contrast to the efficacy observed with anti-5T4 ADC, treatment of both PDXs with cisplatin at the maximum tolerable dose regressed tumors only transiently, and the tumors regrew after treatment was completed ( Figures 6E and S6) . These results highlight the superior long-term efficacy of an ADC that targets TICs as compared to a conventional chemotherapeutic.
Discussion
5T4 and the cellular hierarchy in NSCLC
Using an integrated strategy, we have delineated a cellular hierarchy in NSCLC and identified 5T4 as a clinically relevant marker that can enrich for TICs. We found that 5T4 expression was associated with higher tumorigenic capacity and the undifferentiated state; these results parallel the expression of 5T4 in cycling progenitor cells during embryonic development (18) . The association of 5T4 expression with EMT in tumors, observed in the 87426A1 serum-free culture and the 37622A1 PDX, mirrors the association of 5T4 with EMT in normal development (15) . Our results are consistent with a recent study that described the relationship between EMT and stem cell phenotypes in normal and cancerous tissues (26) .
Expression of 5T4 has been associated with advanced disease and/or poor prognosis in colorectal, ovarian, and gastric cancers (27-29). We found that 5T4 is associated with less differentiated tumor histology, shorter time to recurrence, and worse overall survival in NSCLC. Interestingly, while CD133 was used to isolate NSCLC TICs A, 5T4 expression in NSCLC is associated with worse overall survival in patients.
B, 5T4 expression in NSCLC is associated with shorter time to recurrence in patients. 
